Form 4: Spero Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Debra Zack, Chief Medical Officer of Spero Therapeutics, Inc., reported multiple transactions in common stock on August 3, 2026.
Summary
- Grant/award: acquired 162,311 Common Stock on August 3, 2026; holds 162,311 after (Direct).
- Grant/award: acquired 324,675 Stock option (right to buy) on August 3, 2026; holds 324,675 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Debra Zack — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Grant/award | Common Stock | 162,311 | — | — | 162,311 |
| 2026-08-03 | Grant/award | Stock option (right to buy) | 324,675 | — | — | 324,675 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Grant/award (162,311 shares) |
| 2026-08-03 | Grant/award (324,675 shares) |
Keywords
insider transaction, Form 4, SPRO, Spero Therapeutics, Inc., neutral, Debra Zack
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.